←cognitionstudio.com Practices Science Communications Venture Design One Health
Cognition Science Communications
Our Expertise How We Work What We Build Case Notes Start a conversation →
Home / Case Notes / aTyr · efzofitimod clinical value proposition

How a clinical-stage biotech turned a missed endpoint into a focused, data-defined clinical case

At the moment a hard readout could have defined the company, aTyr took control of its own narrative and moved forward on a sharper clinical case the data itself pointed to.

Challenge Narrative control after a missed primary endpoint
Domain Immunology · pulmonary sarcoidosis
Stage Public (NASDAQ: ATYR) · Ph 3 → Ph 3
Audience Investors · analysts
Mechanism of action — efzofitimod targets NRP2 biology to reset pro-inflammatory macrophages: in the disease state, immune triggers recruit pro-inflammatory macrophages that express inflammatory factors and NRP2, driving MCP-1, TNF-α and IL-6; efzofitimod binds NRP2 to promote a less inflammatory macrophage population, downregulating those drivers of inflammation and fibrosis.
Mechanism of action — efzofitimod modulates NRP2 on activated macrophages, the science the clinical case turns on.

The Science

Efzofitimod is a first-in-class biologic built from tRNA synthetase biology, a protein family with newly understood roles beyond protein synthesis. It fuses the active domain of histidyl-tRNA synthetase to an antibody Fc, and it selectively modulates NRP2 on activated macrophages to resolve inflammation without broadly suppressing the immune system.

aTyr's ambition is to move pulmonary sarcoidosis beyond chronic steroids, the decades-old standard of care. The science is a new class. A new class has no playbook.

Sarcoidosis has heterogeneous lung phenotypes — normal, restrictive, obstructive, mixed and isolated diffusion-limited — with FVC the relevant endpoint only in the restrictive phenotype; a table comparing phenotype prevalence in the Sharp et al. cohort and EFZO-FIT.
Where the data does the narrowing. Sarcoidosis spans several lung phenotypes, and FVC is only clinically relevant in the restrictive one, pointing the go-forward trial to a more homogeneous population.

The Challenge

The market moved quickly to write the story as a failure. But the data was not empty.

In September 2025, EFZO-FIT, the largest interventional trial ever run in pulmonary sarcoidosis, missed its primary endpoint on steroid reduction. Efzofitimod is aTyr's lead program, and the market moved quickly to write the story as a failure. But the data was not empty. It showed where efzofitimod worked. The company had a narrow window, heading into an FDA meeting, to explain what the readout actually meant before someone else's version hardened into fact. Pioneering a new class means the data is the only map, and this map had just been redrawn.

The Work

Shift the story from an endpoint that missed to a population where the drug works, and let the data do the narrowing.

aTyr came to Cognition to build the clinical value proposition and recast the corporate narrative, ahead of the FDA meeting that would set the path forward. The method was the CLVP, the clinical-stage end of our Science Value Proposition chain: what gap in the standard of care the science closes, and for whom.

We built it before the meeting, so the company was ready to tell a coherent story whatever the FDA decided. The move: shift the story from an endpoint that missed to a population where the drug works, and let the data do the narrowing. When the decision came, we locked the corporate deck and investor messaging into one clear thesis.

Benefit on patient-reported outcomes observed in the intention-to-treat population remains consistent in the restrictive population: KSQ-Lung, KSQ-General Health and Fatigue Assessment Scale predicted trajectories over 365 study days favor efzofitimod 5 mg/kg over placebo.
Where the drug works — the benefit on patient-reported outcomes seen in the full ITT population stays consistent in the restrictive population, part of the evidence base for the focused go-forward case.

The Outcome

The readout did not define the company. The response did.

aTyr took control of its own story at the moment it was most at risk of losing it. The recast narrative gave the company a clear, defensible account of what the data showed and where efzofitimod goes next: a focused Phase 3 in the restrictive population, with FVC as the endpoint the FDA views as clinically meaningful. What could have read as retreat read instead as a company following its own evidence.

Restrictive Phase 3
A focused next trial in the population where the drug works — FVC as the endpoint the FDA views as clinically meaningful.
One thesis
Corporate deck and investor messaging locked into a single clear account, ready before the FDA meeting concluded.
Narrative held
The company judged on what the data showed — not on someone else's version of the miss.

Figures are aTyr's own EFZO-FIT trial and platform data.

The takeaway

When a clinical readout surprises you, control belongs to whoever follows the data fastest. A missed endpoint is not a failed thesis. It is the data showing you where to aim.

Related proof

The same craft, other rooms.

See the capability →
eGenesis Brand Strategy — navigating the landscape of xenotransplantation
Xeno · SVP

Turning a fear narrative into the medical-innovation story the field now tells.
CD388 mechanism of action — multi-contact blocking of viral neuraminidase to prevent influenza release
Antivirals · Investor

Turning a pivotal readout into a value proposition the market could price.

Have a readout the market is about to read for you?

Start a conversation →
Explore